Alexander T Pearson

List of Publications by Year
in descending order

80	3,156	257101 24	182168 51
papers	citations	h-index	g-index

86	86	86	4025
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2022, 31, 531-548.	1.9	16
2	A robust and interpretable gene signature for predicting the lymph node status of primary <scp>T1</scp>/<scp>T2</scp> oral cavity squamous cell carcinoma. International Journal of Cancer, 2022, 150, 450-460.	2.3	5
3	Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer, 2022, 22, 17.	1.1	5
4	Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Computational Biology, 2022, 18, e1009822.	1.5	36
5	Abstract P1-08-21: Assessing the impact of treatment interruptions during neoadjuvant therapy in early stage breast cancer. Cancer Research, 2022, 82, P1-08-21-P1-08-21.	0.4	0
6	Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. British Journal of Cancer, 2022, 126, 361-370.	2.9	18
7	Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Network Open, 2022, 5, e227240.	2.8	3
8	A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues. IScience, 2022, 25, 104387.	1.9	6
9	The use of artificial intelligence with uncertainty estimation to predict lung cancer relapse from histopathology.. Journal of Clinical Oncology, 2022, 40, 8549-8549.	0.8	1
10	Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.. Journal of Clinical Oncology, 2022, 40, 2517-2517.	0.8	3
11	Adapting a medical school cancer research education program to the virtual environment.. Journal of Clinical Oncology, 2022, 40, 11029-11029.	0.8	0
12	Nivolumab-based induction chemoimmunotherapy and PD-L1 expression in locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 6075-6075.	0.8	1
13	Drug response prediction in patient-derived xenografts with data augmentation and multimodal deep learning.. Journal of Clinical Oncology, 2022, 40, e13572-e13572.	0.8	0
14	Ovarian cancer through a multi-modal lens. Nature Cancer, 2022, 3, 662-664.	5.7	2
15	Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 1-15.	1.1	19
16	Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Modern Pathology, 2021, 34, 862-874.	2.9	30
17	Academics as leaders in the cancer artificial intelligence revolution. Cancer, 2021, 127, 664-671.	2.0	10
18	Survival of salivary gland cancer stem cells requires mTOR signaling. Cell Death and Disease, 2021, 12, 108.	2.7	6

#	Article	IF	Citations
19	<scp>Longâ€term</scp> neck and shoulder function among survivors of oropharyngeal squamous cell carcinoma treated with chemoradiation as assessed with the neck dissection impairment index. Head and Neck, 2021, 43, 1621-1628.	0.9	2
20	MATHEMATICAL CHARACTERIZATION OF HETEROGENEITY IN A CANCER STEM CELL DRIVEN TUMOR GROWTH MODEL WITH NONLINEAR SELF-RENEWAL. Journal of Biological Systems, 2021, 29, 27-48.	0.5	0
21	Wntâ€“Î²-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nature Immunology, 2021, 22, 471-484.	7.0	39
22	Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.. Journal of Clinical Oncology, 2021, 39, 6011-6011.	0.8	17
23	First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.. Journal of Clinical Oncology, 2021, 39, 2502-2502.	0.8	6
24	A validated mathematical model of FGFR3â€mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer. Computational and Systems Oncology, 2021, 1, e1019.	1.1	9
25	Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer.. Journal of Clinical Oncology, 2021, 39, 6027-6027.	0.8	0
26	Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.. Journal of Clinical Oncology, 2021, 39, TPS6094-TPS6094.	0.8	1
27	Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.. Journal of Clinical Oncology, 2021, 39, 6048-6048.	0.8	5
28	Validation of the RSClin risk calculator using the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, 549-549.	0.8	0
29	Differentiating low and high grade mucoepidermoid carcinoma of the salivary glands using CT radiomics. Gland Surgery, 2021, 10, 1646-1654.	0.5	6
30	Artificial Intelligence Can Cut Costs While Maintaining Accuracy in Colorectal Cancer Genotyping. Frontiers in Oncology, 2021, 11, 630953.	1.3	31
31	Is This the Dawn of Precision Oncology in Head and Neck Cancer?. Journal of Clinical Oncology, 2021, 39, 1839-1841.	0.8	1
32	COVIDomic: A multi-modal cloud-based platform for identification of risk factors associated with COVID-19 severity. PLoS Computational Biology, 2021, 17, e1009183.	1.5	7
33	Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 677051.	1.3	16
34	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nature Communications, 2021, 12, 4423.	5.8	111
35	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	5.9	69
36	The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death and Disease, 2021, 12, 988.	2.7	27

#	Article	IF	Citations
37	Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncology, 2021, 122, 105566.	0.8	10
38	Monitoring Spontaneous Quiescence and Asynchronous Proliferation-Quiescence Decisions in Prostate Cancer Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 728663.	1.8	6
39	Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Letters, 2020, 471, 49-60.	3.2	12
40	Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2020, 1, 789-799.	5.7	343
41	4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22423-22429.	3.3	24
42	Identifying predictors of <scp>HPV</scp>â€related head and neck squamous cell carcinoma progression and survival through patientâ€derived models. International Journal of Cancer, 2020, 147, 3236-3249.	2.3	40
43	Prognosis and Treatment of Nonâ€“Small Cell Lung Cancer in the Age of Deep Learning. JAMA Network Open, 2020, 3, e206368.	2.8	5
44	Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology, 2020, 159, 1406-1416.e11.	0.6	209
45	The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends in Cancer, 2020, 6, 192-204.	3.8	162
46	In Silico Models Accurately Predict In Vivo Response for IL6 Blockade in Head and Neck Cancer. Cancer Research, 2020, 80, 1451-1460.	0.4	6
47	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nature Communications, 2020, 11, 363.	5.8	75
48	Machine Learningâ€“Guided Adjuvant Treatment of Head and Neck Cancer. JAMA Network Open, 2020, 3, e2025881.	2.8	65
49	A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. Journal of Clinical Investigation, 2020, 130, 1405-1416.	3.9	64
50	Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097411.	1.4	12
51	Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.. Journal of Clinical Oncology, 2020, 38, 6516-6516.	0.8	30
52	Machine learning guided adjuvant treatment of head and neck cancer.. Journal of Clinical Oncology, 2020, 38, 6567-6567.	0.8	1
53	Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial.. Journal of Clinical Oncology, 2020, 38, 6575-6575.	0.8	2
54	Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.. Journal of Clinical Oncology, 2020, 38, TPS3173-TPS3173.	0.8	2

#	Article	IF	Citations
55	Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning.. Journal of Clinical Oncology, 2020, 38, e23529-e23529.	0.8	0
56	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, 2019, 25, 1054-1056.	15.2	773
57	Hyperprogressionâ€"Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncology, 2019, 5, 743.	3.4	7
58	Mucoepidermoid Carcinoma. American Journal of Surgical Pathology, 2019, 43, 885-897.	2.1	70
59	The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid Cells. Toxicologic Pathology, 2019, 47, 150-164.	0.9	3
60	Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. Stem Cells, 2019, 37, 257-269.	1.4	58
61	Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2â€"p53 Interaction in Mucoepidermoid Carcinoma. Clinical Cancer Research, 2019, 25, 1588-1600.	3.2	17
62	Extracellular matrix alignment dictates the organization of focal adhesions and directs uniaxial cell migration. APL Bioengineering, 2018, 2, 046107.	3.3	78
63	UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncology, 2018, 87, 21-28.	0.8	23
64	A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment. PLoS Computational Biology, 2018, 14, e1005920.	1.5	26
65	Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. Otolaryngology - Head and Neck Surgery, 2017, 157, 995-997.	1.1	7
66	5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 2516-2527.	3.2	39
67	Therapeutic Inhibition of the MDM2â€"p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clinical Cancer Research, 2017, 23, 1036-1048.	3.2	27
68	Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels. Oncotarget, 2017, 8, 100339-100352.	0.8	24
69	Sampling from single-cell observations to predict tumor cell growth in-vitro and in-vivo. Oncotarget, 2017, 8, 111176-111189.	0.8	2
70	Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget, 2016, 7, 7993-8005.	0.8	63
71	Modeling head and neck cancer stem cell-mediated tumorigenesis. Cellular and Molecular Life Sciences, 2016, 73, 3279-3289.	2.4	7
72	EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells. Cancer Research, 2016, 76, 6396-6409.	0.4	55

#	Article	IF	Citations
73	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investigational New Drugs, 2016, 34, 481-489.	1.2	30
74	Isolation and Characterization of Cancer Stem Cells from Primary Head and Neck Squamous Cell Carcinoma Tumors. Methods in Molecular Biology, 2016, 1395, 241-249.	0.4	6
75	Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clinical Cancer Research, 2016, 22, 3550-3559.	3.2	13
76	Hyperlink-Embedded Journal Articles Improve Statistical Knowledge and Reader Satisfaction. Journal of Graduate Medical Education, 2015, 7, 654-657.	0.6	2
77	Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget, 2015, 6, 22822-22835.	0.8	33
78	BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma. Oral Oncology, 2015, 51, 839-847.	0.8	13
79	ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget, 2015, 6, 26633-26650.	0.8	59
80	Postnatal exposure to methyl mercury from fish consumption: A review and new data from the Seychelles Child Development Study. NeuroToxicology, 2009, 30, 338-349.	1.4	102